Nitromed CEO
Executive Summary
Nitromed CFO Kenneth Bate will succeed interim CEO Jerry Karabelas, the company announces Jan. 22. Bate joined Nitromed in March as part of a management shake-up to jump-start sales of the firm's heart failure therapy for African Americans, BiDil (1"The Pink Sheet" March 27, 2006, p. 14). Bate has held vice president positions at Millennium and Biogen Idec...
You may also be interested in...
NitroMed Aims To Revive BiDil With CEO Change, Managed Care Push
NitroMed's strategy for jump-starting sales of BiDil includes renewed efforts to get favorable formulary placement for the heart failure drug
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.